Mark A Goldsmith, Director, President and Chief Executive Officer, on September 16, 2026, sold 13,988 shares in Revolution Medicines (RVMD) for $2,786,938. Following the Form 4 filing with the SEC, Goldsmith has control over a total of 970,250 common shares of the company, with 253,342 shares held directly and 716,908 controlled indirectly.
SEC Filing:
https://www.sec.gov/Archives/edgar/data/1628171/000124684226000008/xslF345X05/ownership.xml